0
Shares
Pinterest Google+

SILVER SPRING, MD | April 7, 2016 – The Hepatitis Foundation International (HFI) announced the addition of three Board of Director (BOD) members during its Annual Board Meeting, April 2, 2016. The newly elected members include accomplished Congressional, research, and corporate leaders.  Karen Wirth, Chair, BOD stated, “The expansion of HFI’s Board to include such noteworthy individuals comes at an opportune time of significant growth for the Foundation.” Dane Christiansen, Vice Chair, BOD stated, “We look to our next 20 years as an organization positioned to move to the eradication of Hepatitis C and address other areas of liver disease with these key leaders to assist us in our mission.”

As leaders of one of the nation’s first nonprofit organizations established to address hepatitis, these board members contribute to HFI’s strategic agenda across prevention, education, advocacy, research and global outreach. “It is a privilege to serve HFI with these persons who are noted for their individual accomplishments,” said Ivonne Fuller Cameron, HFI CEO. “The knowledge and expertise of our Board gives the Foundation a unique capacity and responsibility to provide access to testing, treatment and linkages to care for the pressing challenges faced by our constituents, patients and their families with hepatitis and/or liver disease. We look forward to engaging our new members in this work.”

HFI New Board Directors Include:

Donna Christensen, MD, served as a Member of Congress for 18 years. She is now the President of Donna M. Christensen, MD, LLC, a consulting company on government, healthcare, and Caribbean issues. Dr. Christensen will be instrumental in attaining the support of current and past Congressional members on key public health issues.

Clark Davis, MBA, National Sales Director at Quintiles Inc., has over 25 years of pharmaceutical industry experience.   His extensive knowledge in the pharmaceutical industry enables HFI to increase access to partnerships within industry as HFI launches its specialty pharmacy and corporate boards.

Lovell A. Jones, PhD, is a Professor of Research at Prairie View A&M University, College of Nursing as well as a Research Professor at Texas A&M University Corpus Christi. Dr. Jones is also the first African American to hold the title of Professor Emeritus from the University of Texas M.D. Anderson Cancer Center and the University of Texas Graduate School of Biomedical Sciences.  Dr. Jones brings a wealth of knowledge in the areas of biochemistry, molecular biology, and biomedical sciences to guide HFI as it advances its research initiatives.

These new HFI Directors join existing members including: Board Chair Karen Wirth, MBA, Chicago, IL; Vice Chair Dane Christiansen, Vice President, Health and Medicine Counsel of Washington, DC; Treasurer Ed Marino, PA-C, North Colorado Medical Center; CEO Ivonne Fuller Cameron, NRPP, MPA and Board Secretary; Jose Bordon, MD, PhD, AAHIVS, Chief, Section of Infectious Diseases, Providence Hospital; Glenn Giles, Partner, Fusion Alternative Investment Partners; Gregory Pappas, MD, PhD, Associate Director, National Device Surveillance at Center for Devices and Radiological Health, FDA; Lisa Pawlowski, PhD, Dean of Academic Affairs, George Mason University Korea; James E. Smith, President, JS Associates.

About HFI

The Hepatitis Foundation International (HFI) is a 501(c) 3 non-profit organization established in 1994 working to eradicate chronic hepatitis for 550 million people globally. HFI is dedicated to increasing and promoting health and wellness; reducing the incidence of preventable liver-related chronic diseases, and lifestyles that negatively impact the liver.  Some of these diseases include: obesity, diabetes, hepatitis, substance abuse, HIV/AIDS, cardiovascular disease and fatty/liver cancer.  The HFI reaches well over 5 million patients and health care professionals annually through our public and private partnerships (www.HepatitisFoundation.org).